TABLE 2.
Summary of cefiderocol broth microdilution resultsa
| Organism(s) | No. of isolates | MIC (μg/ml) |
% (no.) with breakpoint interpretation |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLSI (investigational) |
FDAb
|
EUCAST |
||||||||||
| Range | 50% | 90% | S | I | R | S | I | R | S | R | ||
| Carbapenem-resistant Enterobacterales | 58 | ≤0.03–64 | 0.5 | 8 | 88 (51) | 3 (2) | 9 (5) | 76 (44) | 12 (7) | 12 (7) | 76 (44) | 24 (14) |
| Carbapenemase-producing CRE | 26 | ≤0.03–32 | 0.25 | 4 | 92 (24) | 0 | 8 (2) | 77 (20) | 15 (4) | 8 (2) | 77 (20) | 23 (6) |
| Non-carbapenemase-producing CRE | 32 | 0.06–64 | 0.5 | 16 | 85 (27) | 6 (2) | 9 (3) | 75 (24) | 9 (3) | 16 (5) | 75 (24) | 25 (8) |
| Citrobacter freundii complex | 2 | 0.06–8 | 0.06 | 8 | 50 (1) | 50 (1) | 0 | 50 (1) | 0 | 50 (1) | 50 (1) | 1 (50) |
| Enterobacter cloacae complex | 15 | 0.06–64 | 0.5 | 16 | 90 (12) | 7 (1) | 13 (2) | 60 (9) | 20 (3) | 20 (3) | 60 (9) | 40 (6) |
| Escherichia coli | 15 | 0.06–2 | 0.25 | 1 | 100 (15) | 0 | 0 | 100 (15) | 0 | 0 | 100 (15) | 0 |
| Klebsiella aerogenes | 2 | 0.5–1 | 0.5 | 1 | 100 (2) | 0 | 0 | 100 (2) | 0 | 0 | 100 (2) | 0 |
| Klebsiella oxytoca | 6 | ≤0.03–1 | 0.06 | 1 | 100 (6) | 0 | 0 | 100 (6) | 0 | 0 | 100 (6) | 0 |
| Klebsiella pneumoniae | 15 | 0.06–32 | 2 | 32 | 80 (12) | 0 | 20 (3) | 53 (8) | 27 (4) | 20 (3) | 53 (8) | 47 (7) |
| Serratia marcescens | 3 | ≤0.03–2 | ≤0.03 | 2 | 100 (3) | 0 | 0 | 100 (3) | 0 | 0 | 100 (3) | 0 |
| Non-glucose-fermenting Gram-negative bacilli | 50 | ≤0.03–8 | 0.5 | 4 | 92 (36) | 5 (2) | 3 (1) | 57 (8) | 14 (2) | 29 (4) | 74 (37) | 26 (13) |
| Pseudomonas aeruginosa | 14 | 0.5–8 | 1 | 8 | 93 (13) | 7 (1) | 0 | 57 (8) | 14 (2) | 29 (4) | 71 (10) | 29 (4) |
| Acinetobacter baumannii complex | 14 | 0.06 | 4 | 8 | 86 (12) | 7 (1) | 7 (1) | 36 (5)c | 64 (9)c | |||
| Achromobacter xylosoxidans | 8 | 0.06–1 | 0.25 | 1 | 100 (8)c | 0 | ||||||
| Burkholderia cepacia complex | 3 | 0.12–0.25 | 0.12 | 0.25 | 100 (3)c | 0 | ||||||
| Stenotrophomonas maltophilia | 11 | ≤0.03–0.5 | 0.12 | 0.25 | 100 (11) | 0 | 0 | 100 (11)c | 0 | |||
| All isolates | 108 | ≤0.03–64 | 0.5 | 4 | 90 (87) | 4 (4) | 6 (6) | 72 (52) | 13 (9) | 15 (11) | 75 (81) | 25 (27) |
a
CLSI, Clinical and Laboratory Standards Institute; FDA, U.S. Food and Drug Administration; EUCAST, European Committee on Antimicrobial Susceptibility Testing; S, susceptible; I, intermediate; R, resistant.
b
Breakpoints used for this analysis were prior to the 28 September 2020 update. FDA breakpoints for the Enterobacterales (listed as Enterobacteriaceae on the FDA website) are specific for E. coli, K. pneumoniae, P. mirabilis, and E. cloacae complex. These breakpoints were used to interpret results for all Enterobacterales in this study.
c
Non-species-specific pharmacokinetic-pharmacodynamic (PK-PD) breakpoints.